Tower Research Capital LLC (Trc) Onconova Therapeutics, Inc. Transaction History

Tower Research Capital LLC (Trc)

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$0.57 - $1.0 $11 - $21	21 Added 0.6%	3,508 $2,000
Q1 2024 May 15, 2024	SELL	$0.67 - $1.01 $41 - $62	-62 Reduced 1.75%	3,487 $3,000
Q4 2023 Feb 13, 2024	SELL	$0.62 - $0.79 $144 - $184	-233 Reduced 6.16%	3,549 $2,000
Q3 2023 Nov 14, 2023	BUY	$0.71 - $1.15 $166 - $269	234 Added 6.6%	3,782 $2,000
Q2 2023 Aug 14, 2023	SELL	$0.67 - $1.42 $1,136 - $2,409	-1,697 Reduced 32.35%	3,548 $4,000
Q1 2023 May 09, 2023	BUY	$0.69 - $1.42 $3,619 - $7,447	5,245 New	5,245 $4,000
Q2 2022 Aug 15, 2022	SELL	$1.04 - $1.9 $1,538 - $2,810	-1,479 Closed	0 $0
Q1 2022 May 12, 2022	SELL	$1.46 - $2.82 $2,360 - $4,559	-1,617 Reduced 52.23%	1,479 $3,000
Q4 2021 Feb 14, 2022	SELL	$2.49 - $3.73 $6,879 - $10,305	-2,763 Reduced 47.16%	3,096 $8,000
Q3 2021 Nov 15, 2021	BUY	$3.81 - $6.76 $22,162 - $39,322	5,817 Added 13850.0%	5,859 $22,000
Q2 2021 Aug 16, 2021	BUY	$6.28 - $16.2 $263 - $680	42 New	42 $0

276K

Ticker ONTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 20,895,600
Market Cap $12.3M
Description
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.